Healthcare / Diagnostics & ResearchStockholm
$5.26
-0.04 (-0.75%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-12.3M · quality 75.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
20/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$171M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-14.9%
↓Gross Margin
64.8%
↑Debt/Equity
0.24
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+11.5%
FCF CAGR
—
FCF margin
-21.2%
FCF / Net income
1.06x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $58.0M · net income $-11.6M · FCF $-12.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $58.0M | $58.0M | $57.7M | $49.9M | $41.8M |
| Net Income | $-11.6M | $-11.6M | $-11.2M | $-22.1M | $-24.9M |
| EBITDA | $-8.3M | $-8.3M | $-7.7M | $-10.4M | $-15.5M |
| EPS | -0.39 | -0.39 | -0.41 | -0.91 | -1.03 |
| Gross Margin | 64.8% | 64.8% | 66.9% | 70.0% | 65.4% |
| Operating Margin | -19.0% | -19.0% | -22.0% | -30.0% | -48.3% |
| Net Margin | -20.0% | -20.0% | -19.4% | -44.3% | -59.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.24 | 0.24 | 0.08 | 0.16 | 0.01 |
| Current Ratio | 2.95 | 2.95 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-12.3M | $-12.3M | $-11.0M | $-20.3M | $-18.7M |
| Returns | |||||
| ROE | -14.9% | -14.9% | -12.3% | -33.4% | -27.8% |
| Valuation | |||||
| P/B | 2.00 | 2.00 | 2.10 | 2.63 | 3.44 |
| Growth & Yield | |||||
| Revenue Growth | 0.5% | 0.5% | 15.7% | 19.4% | — |
| EPS Growth | 4.9% | 4.9% | 54.9% | 11.7% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-10.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.41 → -0.39
Residual
-10.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.